Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives

Key Takeaways for Concurrent Biomarker Testing in NSCLC

Overview of PERSEUS, IsKia, and GMMG-HD7

Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

Looking Ahead and Key Takeaways

Optimizing Regimens and Managing Adverse Events in TIE NDMM

Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLL

Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma

Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCL

Dr Sharma on the Impact of Frontline Treatment Advances in Advanced Bladder Cancer